ArticleThrombosis journal2026
Fibrinogen-to-albumin ratio and risk of thrombotic diseases incidence.
Article in Thrombosis journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe fibrinogen-to-albumin ratio (FAR) is linked to cardiovascular diseases, but its association with thrombotic diseases in the general population remains unclear.
objectiveTo investigate the relationship between FAR and thrombotic diseases and assess their dose-response association.
methodsThis prospective cohort study included 18,208 participants (mean age 53.2 years, 41.9% female) from the Xifei community cohort (2011–2021). Participants were categorized into FAR quintiles (Q1–Q5). Restricted cubic spline and Cox regression models were used to assess the associations between FAR and thrombotic risk.
resultsOver follow-up of 8 years, 1,373 thrombotic events occurred. Compared to the group of lowest FAR, the group of highest FAR showed significantly increased risks of combined arterial and venous thrombosis (HR = 1.36, 95% CI 1.08–1.70), arterial thrombosis (HR = 1.35, 1.07–1.70), and stroke (HR = 1.36, 1.06–1.76). Risks for acute myocardial infarction, venous thromboembolism, deep venous thrombosis, and pulmonary embolism were not statistically significant. A nonlinear dose-response relationship between FAR and thrombotic risk was observed. CONCLUSIONS AND RELEVANCE: Higher baseline FAR was associated with an elevated risk of arterial and venous thrombosis, arterial thrombosis, and stroke, whereas associations with acute myocardial infarction and venous outcomes (VTE, DVT, and PE) were not statistically significant. These findings suggest that FAR may be a useful biomarker for thrombotic risk assessment in the general population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.